• Clinical Decision Support System (CADIMS) for MS Diagnostic

  NCT03205280

  CompletedObservationalUpdated Apr 12, 2023
• Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme

  NCT03471338

  CompletedInterventionalNot ApplicableUpdated Jul 25, 2025
• Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination

  NCT07135752

  RecruitingInterventionalNot ApplicableUpdated Jan 21, 2026
• Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

  NCT05949580

  SuspendedObservationalUpdated Jul 20, 2026
• Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS

  NCT05510817

  Unknown statusInterventionalNot ApplicableUpdated Dec 5, 2023
• A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

  NCT07189325

  RecruitingInterventionalPhase 3Updated Jun 23, 2026

ClinicalTrials.gov ID

NCT07647952

Lead Sponsor

Nantes University HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

448Estimated

Last Update Posted

Jun 15, 2026Actual

Start Date

Jun 30, 2026Estimated

Primary Completion Date

Oct 31, 2027Estimated

Completion Date

Jul 31, 2028Estimated

Official Title

PRIMUS a Multi-centre, Controlled, Cluster-randomised, Open Study of Multiple Impacts of CDSS Use in Multiple Sclerosis : Real World Usage for Real World Evidence

Brief Summary

This study evaluates a Clinical Decision Support System (CDSS), named PRIMUS, designed to support therapeutic decision-making in MS. The CDSS is based on a validated reference database integrating retrospective data from randomized controlled trials and the French national MS cohort (Observatoire Français de la Sclérose en Plaques, OFSEP). This reference database consists of synthetic data derived from these sources.

PRIMUS enables visualization of disease activity at 1 and 2 years under different therapeutic scenarios, based on clinical and MRI characteristics of patients similar to the patient of interest. The CDSS PRIMUS aims to support informed and individualized treatment decisions. Because MRI is a critical marker of disease activity previously acquired MRI scans will be reanalyzed using automated segmentation and validated by a radiologist to standardize lesion assessment across centers. The results will be displayed to the neurologist and, if appropriate shown to the patient using a dedicated viewer, and can be discussed during the consultation.

A cluster-randomized controlled trial, with hospitals as the unit, will be conducted to evaluate the impact of the CDSS on treatment decision-making in patients with relapsing-remitting MS. The primary objective is to assess whether the use of the CDSS influences therapeutic choices during clinical consultations.

The study hypothesis is that use of the CDSS will increase the proportion of high-efficacy treatments initiated or selected, compared with usual care without CDSS support.

In parallel, an optional sub-study using a mixed-methods approach will explore clinicians' and patients' perceptions of, and interactions with, the CDSS.

• Relapsing - Remitting Multiple Sclerosis

• Clinical decision support system

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Men and women aged >18 and ≤50 years.

• Patients with relapsing-remitting multiple sclerosis (RRMS) according to the McDonald 2024 criteria.

• Patients for whom a change in therapeutic management is being considered due to:

  • intolerance to treatment or personal preference in the absence of inflammatory activity, whether patients are:

    • on a moderately effective disease-modifying therapy [Interferon beta; Glatiramer acetate; Teriflunomide; Dimethyl fumarate; Diroximel fumarate] for at least 12 months without interruption
    • on anti-S1P therapy [Fingolimod; Ponesimod] for at least 12 months without interruption or

  • recent inflammatory activity (relapse or at least one T1 Gd+ lesion or one new T2 lesion) reported or observed at inclusion, whether patients are:

    • treatment-naïve
    • on a moderately effective disease-modifying therapy for at least 6 months or on anti-S1P therapy for at least 6 months
    • untreated for at least one year

• Patients with MRI follow-up including at least one 3D brain FLAIR sequence and a T1 Gd+ sequence in the case of a re-baseline brain MRI within the past 6 months.

• Patients whose MRI scans are available for download on the day of consultation.

• Patients affiliated with or beneficiaries of a social security system.

• Patients able to provide written informed consent. For women of childbearing potential, use of an effective method of contraception throughout the study in accordance with the recommendations of the Clinical Trials Coordination Group

Exclusion Criteria:

• Patients with a progressive form of multiple sclerosis (primary or secondary).
• Patients with current or past history of other autoimmune diseases.
• Patients with uncontrolled disease, other than active MS.
• Patients exposed to Mitoxantrone, Alemtuzumab, or Cladribine within the 3 years prior to inclusion.
• Patients exposed to Ocrelizumab or Rituximab within the 18 months prior to inclusion.
• Patients exposed to Ofatumumab within the 12 months prior to inclusion.
• Patients receiving high-efficacy disease-modifying therapy [Natalizumab; Ofatumumab; Alemtuzumab; Cladribine; Mitoxantrone; Ocrelizumab], or Rituximab, with the exception of S1P receptor modulators.
• Patients receiving Mycophenolate mofetil, azathioprine, cyclophosphamide (Endoxan), or having undergone stem cell transplantation.
• Patients participating in another clinical trial, whether therapeutic or not, that could interfere with the objectives of the study.
• Patients who have participated in a therapeutic trial within the 24 months prior to inclusion.
• Pregnant or breastfeeding women, or those planning pregnancy during the study.
• Patients under legal protection (guardianship, curatorship, or other protective measures).

Primary Purpose

Other

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Nantes University HospitalOTHER

renato.colamarino@ch-antibes.fr04 97 24 77 25 / 82 15

aurelie.ruet@chu-bordeaux.fr05 56 79 55 21

aurore.jourdain@chu-brest.fr02 98 34 73 00

branger-p@chu-caen.fr02 31 06 46 17

pclavelou@chu-clermontferrand.fr04 73 75 22 01

francois.sellal@ch-colmar.fr03 89 12 41 50

alain.creange@aphp.fr01 49 81 23 15

thibault.moreau@chu-dijon.fr03 80 29 52 70

thomas.ancel@ch-ed.fr

OCasez@chu-grenoble.fr04 76 76 58 71

pascal.lejeune@ght85.fr02 51 44 62 58

helene.zephir@chu-lille.fr03 20 44 57 65

sandra.vukusic@chu-lyon.fr04 72 68 13 13

jean.PELLETIER@ap-hm.fr04 91 38 59 41

basile.wittwer@chr-metz-thionville.fr03 87 18 61 62

labauge@yahoo.fr04 67 33 94 69

g.mathey@chru-nancy.frnk

lebrun.c@chu-nice.fr04 92 03 85 27

eric.thouvenot@chu-nimes.fr04 66 68 32 61

olivier.heinzlef@ght-yvelinesnord.fr01 39 27 41 92

amelie.dos-santos@chu-poitiers.fr0253482852

laure.michel@chu-rennes.fr02 99 28 42 94

bertrand.bourre@chu-rouen.fr+332 32 88 09 68

francois.lallement@armorsante.bzh02 96 01 75 00

jerome.de.seze@chru-strasbourg.fr03 88 12 85 43

ciron.j@chu-toulouse.fr05 61 77 91 06

i.doghri@chu-tours.fr02 47 47 80 23